Wall Street brokerages forecast that Lion Biotechnologies Inc (NASDAQ:LBIO) will report earnings of ($0.36) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Lion Biotechnologies’ earnings, with estimates ranging from ($0.39) to ($0.28). Lion Biotechnologies reported earnings of ($0.23) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 56.5%. The firm is scheduled to issue its next earnings report on Monday, August 14th.
On average, analysts expect that Lion Biotechnologies will report full year earnings of ($1.39) per share for the current financial year, with EPS estimates ranging from ($1.55) to ($1.16). For the next year, analysts forecast that the business will report earnings of ($1.44) per share, with EPS estimates ranging from ($1.74) to ($1.11). Zacks’ EPS calculations are a mean average based on a survey of research analysts that cover Lion Biotechnologies.
Lion Biotechnologies (NASDAQ:LBIO) last released its earnings results on Monday, May 1st. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.05.
LBIO has been the subject of a number of research analyst reports. Zacks Investment Research cut Lion Biotechnologies from a “hold” rating to a “sell” rating in a report on Friday, February 17th. Jefferies Group LLC lowered their price target on Lion Biotechnologies from $13.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, March 8th. Roth Capital reiterated a “buy” rating on shares of Lion Biotechnologies in a report on Wednesday, February 15th. Wells Fargo & Co initiated coverage on Lion Biotechnologies in a report on Friday, March 17th. They set an “outperform” rating for the company. Finally, FBR & Co set a $17.00 price target on Lion Biotechnologies and gave the stock a “buy” rating in a report on Wednesday, March 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $16.29.
Lion Biotechnologies (NASDAQ:LBIO) traded down 4.92% during midday trading on Monday, hitting $5.80. 531,837 shares of the stock traded hands. Lion Biotechnologies has a 12 month low of $5.48 and a 12 month high of $9.58. The company’s 50 day moving average price is $6.41 and its 200 day moving average price is $6.97. The firm’s market cap is $361.64 million.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/05/20/brokerages-expect-lion-biotechnologies-inc-lbio-will-announce-earnings-of-0-36-per-share.html.
A number of institutional investors have recently made changes to their positions in LBIO. Parametric Portfolio Associates LLC boosted its position in shares of Lion Biotechnologies by 1.4% in the first quarter. Parametric Portfolio Associates LLC now owns 15,891 shares of the biotechnology company’s stock worth $118,000 after buying an additional 217 shares during the period. Bank of America Corp DE boosted its position in shares of Lion Biotechnologies by 77.1% in the first quarter. Bank of America Corp DE now owns 16,870 shares of the biotechnology company’s stock worth $126,000 after buying an additional 7,344 shares during the period. Trexquant Investment LP purchased a new position in shares of Lion Biotechnologies during the first quarter worth approximately $197,000. American International Group Inc. boosted its position in shares of Lion Biotechnologies by 30.6% in the first quarter. American International Group Inc. now owns 34,187 shares of the biotechnology company’s stock worth $255,000 after buying an additional 8,007 shares during the period. Finally, Credit Suisse AG boosted its position in shares of Lion Biotechnologies by 3.9% in the first quarter. Credit Suisse AG now owns 35,603 shares of the biotechnology company’s stock worth $265,000 after buying an additional 1,351 shares during the period. Institutional investors own 75.97% of the company’s stock.
About Lion Biotechnologies
Lion Biotechnologies, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lion Biotechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.